GeneFerm Biotechnology Co

GeneFerm Biotechnology Co EBIT per Share

The EBIT per Share of GeneFerm Biotechnology Co (1796.TWO) as of Oct 17, 2026 is 1.11 TWD. In the previous year, EBIT per Share was -0.86 TWD — a change of -229.72% (higher).

EBIT per Share

1.11TWD

YoY

-229.72%

Last updated:

EBIT per Share of GeneFerm Biotechnology Co is 2025 1.11 TWD. EBIT per Share of GeneFerm Biotechnology Co was 2024 -0.86 TWD. It decreases by -229.72% higher compared to the previous year.

The GeneFerm Biotechnology Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
0.24 TWD
Jan 1, 2019
-0.56 TWD
Jan 1, 2020
0.63 TWD
Jan 1, 2021
1.94 TWD
Jan 1, 2022
2.73 TWD
Jan 1, 2023
3.75 TWD
Jan 1, 2024
-0.86 TWD
Jan 1, 2025
1.11 TWD
The GeneFerm Biotechnology Co EBIT per Share history
YEAREBIT per ShareYoY
1.11TWD-229.72%
-0.86TWD-122.80%
3.75TWD+37.36%
2.73TWD+40.84%
1.94TWD+208.96%
0.63TWD-211.39%
-0.56TWD-338.04%
0.24TWD-72.86%
0.87TWD-81.00%
4.59TWD+101.03%
2.29TWD-396.48%
-0.77TWD-365.29%
0.29TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneFerm Biotechnology Co Stock analysis

What does GeneFerm Biotechnology Co do? GeneFerm Biotechnology Co Ltd is a company based in Tainan, Taiwan, operating within the Consumer Staples sector and the Consumer products industry. It went public on July 26, 2016, with the ticker symbol 1796.TWO and ISIN TW0001796001. The company focuses on the manufacture and sale of health food and dietary supplements. Its product portfolio includes fermented products, medicinal mushrooms, lactic acid bacteria products, and fruit and vegetable fermented concentrates. GeneFerm also offers related manufacturing services, as well as health food design, research, and development services. The company's headquarters are located in Tainan, Taiwan, and it maintains a website at https://www.geneferm.com/. As a publicly traded entity, GeneFerm Biotechnology Co Ltd is listed on the Taiwan Stock Exchange, providing investors with access to its financial performance and corporate activities. The company's operations are centered around the development and production of health-focused food and supplement products, emphasizing natural and fermented ingredients. Its services extend beyond product manufacturing to include design, R&D, and manufacturing support for health food solutions. The firm has been active in the market since its IPO in 2016, contributing to the consumer staples sector with its specialized health food offerings. GeneFerm Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneFerm Biotechnology Co stock

EBIT per Share of GeneFerm Biotechnology Co is 1.11 TWD in 2025.

EBIT per Share of GeneFerm Biotechnology Co changed from -0.86 TWD to 1.11 TWD, representing a -229.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share GeneFerm Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GeneFerm Biotechnology Co

All Key Metrics — GeneFerm Biotechnology Co